Kallmark H, Einarsson JT, Nilsson JA, et al. - This study sought to correlate the real-life effectiveness of biologic therapy (a biologic disease-modifying antirheumatic drug plus methotrexate [MTX]) vs triple therapy (MTX plus sulfasalazine plus hydroxychloroquine/chloroquine) for sustained remission of rheumatoid arthritis (RA). Researchers included RA patients who were registered in the nationwide Swedish Rheumatology Quality Register between 2000 and 2012 and were receiving biologic or triple therapy as a first treatment strategy after MTX monotherapy. They used survival analyses to compare treatment groups at any time during follow-up irrespective of therapy retention. The study enrolled a total of 1,502 patients (1,155 receiving biologic therapy and 347 receiving triple therapy). Biologic therapy was more effective for remaining on therapy and achieving sustained remission among patients starting biologic or triple therapy. Nevertheless, they observed similar probabilities for achieving sustained remission among patients remaining on therapy and at any time during follow-up irrespective of therapy retention. The data demonstrate that triple therapy may still be an alternative to biologic therapy without hampering future chances of obtaining sustained remission for certain RA patients, although the likelihood of reaching sustained remission is higher with biologic therapy.